ReviewJournal of clinical medicine2022
Depression and Quality of Life in Patients with Gliomas: A Narrative Review.
Review in Journal of clinical medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Understanding the Trajectory of Depressive Symptoms in Newly Diagnosed High-Grade Glioma Patients-A Meta-Analysis.Psycho-oncology · 2025Pooled it
- Antidepressant drugs and risk of developing glioma: a national registry-based case-control study and a meta-analysis.American journal of epidemiology · 2024Pooled it
- The effect of depression and anxiety on survival in patients with glioma: a systematic review and meta-analysis.Journal of neuro-oncology · 2024Pooled it
- Discovery of novel Kir4.1 inhibitors based on serdemetan with potential therapy for glioblastoma-depression comorbidity.Pharmaceutical science advances · 2026Article
- Psychological distress as a putative host-state determinant of cancer immunotherapy response.Frontiers in immunology · 2026Review
- Plasma biomarker ORAI1 as a dual prognostic value for survival and postoperative quality of life in glioma patients.Scientific reports · 2025Article
- Brain Tumors, AI and Psychiatry: Predicting Tumor-Associated Psychiatric Syndromes with Machine Learning and Biomarkers.International journal of molecular sciences · 2025Review
- Use of psychotropic medications among glioma patients in Denmark, Norway, Sweden, and Wales.Journal of neuro-oncology · 2025Article
- Prevalence and Independent Risk Factors of Anxiety and Depression Symptoms in Glioma Patients: A Cross-Sectional Analysis.Psychiatry and clinical psychopharmacology · 2025Article
- Symptom management in isocitrate dehydrogenase mutant glioma.Neuro-oncology practice · 2025Review
- Health-related quality of life in 62 patients with diffuse low-grade glioma during a non-therapeutic and progression-free phase: a cross-sectional study.Journal of neuro-oncology · 2025Article
- Current status of advance care planning, palliative care consultation, and end-of-life care in patients with glioblastoma in South Korea.The oncologist · 2024Article
- The association of symptomatic vitreous floaters with depression and anxiety.International ophthalmology · 2024Article
- Review
- Influence of neuropathological diagnosis on psychooncological distress in neurooncological patients - a retrospective cross-sectional analysis.Frontiers in oncology · 2024Article
- Review
- Unraveling the transcriptomic signatures of Parkinson's disease and major depression using single-cell and bulk data.Frontiers in aging neuroscience · 2023Article
- Estimating the Prognosis of Low-Grade Glioma with Gene Attention Using Multi-Omics and Multi-Modal Schemes.Biology · 2022Article
- Impact of antidepressant use on survival outcomes in glioma patients: A systematic review and meta-analysis.Neuro-oncology advancesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
In patients with gliomas, depression is a common complication that may cause severe psychological barriers and deteriorate the patient's quality of life (QoL). Currently, the Hospital Anxiety and Depression Scale (HADS) is the most commonly used tool to diagnose depression in patients with gliomas. Female sex, unmarried status, low education level, high tumor grade, and a history of mental illness may increase the risks of depression and depressive symptoms in patients with gliomas. The QoL of patients with gliomas can be directly reduced by depression. Therefore, the evaluation and intervention of mood disorders could improve the overall QoL of patients with gliomas. Antidepressant use has become a treatment strategy for patients with gliomas and comorbid depression. This narrative review summarizes the current issues related to depression in patients with gliomas, including the prevalence, risk factors, and diagnostic criteria of depression as well as changes in QoL caused by comorbid depression and antidepressant use. The purpose of this review is to guide clinicians to assess the psychological status of patients with gliomas and to provide clinicians and oncologists with a new treatment strategy to improve the prognosis of such patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.